Live Breaking News & Updates on Hillstream biopharma

Stay informed with the latest breaking news from Hillstream biopharma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Hillstream biopharma and stay connected to the pulse of your community

Histone Deacetylase 6 Drug Pipeline Research Report 2024:

Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The

Dublin , Ireland , Regenacy-pharmaceuticalsricolinostat , Hillstream-biopharma , Karus-therapeutics , Chong-kun-dang-pharmaceuticals , Chong-kun-dang , Pipeline-development-activities , Celgene-corporation , Cstone-pharmaceuticals , Regenacy-pharmaceuticals , Shuttle-pharmaceuticals

Hillstream BioPharma (NASDAQ:HILS) Stock Price Down 6.6%

Hillstream BioPharma, Inc. (NASDAQ:HILS – Get Free Report) dropped 6.6% during mid-day trading on Friday . The company traded as low as $0.43 and last traded at $0.44. Approximately 482,816 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 1,388,685 shares. The stock had previously closed at $0.47. […]

Hillstream-biopharma , Hillstream-biopharma-company-profile , Hillstream-biopharma-inc , Geode-capital-management , Nasdaq , Citadel-advisors , Get-free-report , Biopharma-trading-down , Capital-management , Jane-street-group , Hillstream-biopharma-daily , Nasdaq-hils

Tharimmune (THAR) versus Its Peers Financial Comparison

Tharimmune (NASDAQ:THAR – Get Free Report) is one of 913 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Tharimmune to similar companies based on the strength of its analyst recommendations, risk, profitability, institutional ownership, dividends, valuation and earnings. Profitability This table compares Tharimmune […]

New-jersey , United-states , Hillstream-biopharma-inc , Minotaur-therapeutics-inc , Tharimmune-inc , Get-free-report , Given-tharimmune , Minotaur-therapeutics , Hillstream-biopharma , Tharimmune-daily , Tharimmune

Cary biotech startup lands licensing deal for potential chronic itchy skin treatment

Avior Bio, a small Cary startup developing a treatment for pruritus, or chronic itchy skin, has secured an agreement to license its clinical-stage therapy to a New Jersey pharmaceutical company.

Bridgewater , North-carolina , United-states , New-jersey , Hillstream-biopharma , Randy-milby , Niraj-vasisht , Biodelivery-sciences-international , Tharimmune-inc , Carolina-biotechnology-center , Avior-bio , North-carolina-biotechnology

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Bridgewater , Nova-scotia , Canada , Hillstream-biopharma , Randy-milby , Nasdaq , Avior-inc , Omniab-inc , Avior-bio , Exchange-commission , Tharimmune-inc , Executes-exclusive-global-licensing-agreement

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
bostonstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bostonstar.com Daily Mail and Mail on Sunday newspapers.

Hillstream-biopharma , Randy-milby , Avior-bio , Omniab-inc , Tharimmune-inc , Nasdaq , Exchange-commission , Avior-inc , Private-securities-litigation-reform-act , Risk-factors , Annual-report

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
baltimorestar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baltimorestar.com Daily Mail and Mail on Sunday newspapers.

Hillstream-biopharma , Randy-milby , Tharimmune-inc , Omniab-inc , Avior-bio , Avior-inc , Exchange-commission , Nasdaq , Private-securities-litigation-reform-act , Risk-factors , Annual-report

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

Randy-milby , Hillstream-biopharma , Nasdaq , Omniab-inc , Avior-inc , Avior-bio , Exchange-commission , Tharimmune-inc , Private-securities-litigation-reform-act , Risk-factors , Annual-report

Hillstream BioPharma, Inc. will Change its Ticker to THAR from HILS

Effective September 25, 2023, Hillstream BioPharma, Inc. will change its Nasdaq Capital Market stock ticker symbol to THAR from HILS....

Hillstream-biopharma-inc , Effective-september , Hillstream-biopharma , Nasdaq-capital-market , Markets ,

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset ...

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset ...

Greece , Greek , Randy-milby , Hillstream-biopharma , News-network , Drug-administration , Hillstream-biopharma-inc , Omniab-inc , Exchange-commission , Tharimmune-inc , Nasdaq , Monday-september